Company news
Gyre Therapeutics, Inc. news in 2024
Gyre Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
November 12, 2024
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
October 21, 2024
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference
September 30, 2024
Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
September 3, 2024
Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
August 12, 2024
Gyre Therapeutics to Present at Sidoti Virtual Investor Conference
August 8, 2024
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
August 7, 2024
Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia
July 1, 2024
Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
June 17, 2024
Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
May 29, 2024
Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
May 27, 2024
Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 8, 2024
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
March 25, 2024
Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
March 20, 2024